Fang Liu et al. reported the initial findings of preclinical and clinical phase I trials utilizing CLL1-CD33 CAR-T cells, since CLL1 and CD33 are often employed as targets in AML treatment [81]. Here, CD33 is linked to acute myeloid leukemia.